U.S. FDA Panel Backs Celltrion Copycat of Roche Blood Cancer Drug U.S. FDA Panel Backs Celltrion Copycat of Roche Blood Cancer Drug

Celltrion Inc ' s biosimilar of Roche Holding AG ' s blockbuster cancer drug, Rituxan (rituximab), on Wednesday won unanimous backing from an advisory panel to the U.S. Food and Drug Administration.Reuters Health Information
Source: Medscape Medical News Headlines - Category: Consumer Health News Tags: Medscape Today News Source Type: news